ClinicalTrials.gg
Active, not recruitingNCT07736391Updated Jul 30, 2026

A Study of SYH2069 Injection in Healthy Participants

A Phase 1 interventional study of SYH2069 Injection and Placebo in Overweight or Obesity and Diabetes, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
270th of 502
104 · median 120
Started
2026
with 133 others
Phase 1
93 of 600
29 open now
Primary completion
2026-07
later than 74 of 280 live
Registered
523rd of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 270th largest by enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 93 in phase 1, reaches primary completion later than 74 of the 280 other live ones, and was the 523rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.

03

Conditions studied

  • Overweight or Obesity
  • Diabetes

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 104 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the content, process and possible adverse reactions of the trial, and voluntarily sign the form before the trial;
  • Male or female, aged 18-55 years (inclusive, based on the time of signing the informed consent form) at screening;
  • At screening, male body weight ≥ 50 kg, female body weight ≥ 45 kg, SAD study: between 19 and 28 kg/m2 inclusive), MAD study: BMI between 24 and 35 kg/m 2 inclusive);
  • Subjects (including partners) have no plans to have children from the time of signing the informed consent form until 6 months after the last dose, and agree to use highly effective measures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergies to GLP-1 or GIP receptor agonists or any components of the product, or allergic constitution (allergies to multiple drugs and foods);
  • Abnormal results of vital signs, physical examination, laboratory tests, chest X-ray, ultrasound, and , etc., which are judged by the investigator to be and unsuitable for participation in the study. Among them, the following conditions were not excluded in the MAD study: (1) systolic blood pressure \<160 mmHg, diastolic blood pressure \<100 mmHg; (2) TG ≤ 3.42 mmol/L, TC ≤ 7.75 mmol/L (regardless of whether LDLC is abnormal), and abnormal HDLC; (3) \< 2 times × , AST \< 2 times × upper limit of normal, GGT \< 2.5 times × upper limit of normal, total \< 1.5 times × upper limit of normal; (4) Blood uric acid \<480 μmol/L and never accompanied by physiological abnormalities (gout, etc.); (5) Ultrasound shows fatty liver and excludes causes other than metabolism;
  • Meet any of the following at screening: (1) > upper limit of normal, or fasting blood glucose ≤ 3.9 mmol/L or ≥ 6.1 mmol/L; (2) Calcitonin ≥ 50 ng/L; (3) \< 90 mL/min/1.73m 2; (4) TSH exceeds the normal reference range;
  • Patients with prolonged /QTc interval at screening (QTcF > 450 ms), or have a history of risk factors for torsades de pointes (such as family history of heart failure/cardiomyopathy or long QT syndrome), or are taking concomitant medications that prolong the QT/QTc interval;
  • Those who are positive for any of surface antigen, virus antibody, antibody, and Treponema pallidum antibody;
  • History or presence of major cardiovascular, respiratory, digestive, urinary, hematological, endocrine, immune or nervous system diseases;
  • Subjects with severe trauma or major surgery within 6 months prior to screening, or planned to undergo surgery during the trial;
  • Patients with thyroid nodules diagnosed as C-TIRADS category 3 or above in the past or during the screening period;
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2, or history of pancreatitis or acute or chronic gallbladder disease;
  • Those with a history of malignant tumors, mental illness, depression, anxiety, or epilepsy;
  • History of clinical gastric emptying abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcer);
  • Previous gastrointestinal surgery leading to malabsorption, or long-term use of drugs that have a direct effect on gastrointestinal motility. e.g., bariatric surgery or procedures (e.g., gastric banding), or use of GLP-1 or GIP receptor agonists or drugs or products that, in the opinion of the investigator, may cause weight change and affect weight assessment within 3 months prior to dosing.
  • Body weight change ≥ 5% within 3 months prior to screening (inclusive) (only applicable to MAD study;
  • Those who have symptoms such as dermatitis or skin abnormalities at and around the administration site;
  • Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 2 weeks before screening;
  • Use of drugs that may affect glucose metabolism (e.g., systemic , non-selective beta-blockers, monoamine oxidase inhibitors) within 1 month before screening;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    SYH2069 Injection Experimental

    Single-ascending dose and multiple-ascending dose

    Drug: SYH2069 Injection

  • Placebo comparator
    Placebo Comparator

    Single-ascending dose and multiple-ascending dose

    Drug: Placebo

Interventions

  • A subcutaneous injection in the abdomen of the corresponding dose of SYH2069 Injection according to the assigned dose cohort.

  • DrugPlacebo

    A subcutaneous injection in the abdomen of the corresponding dose of Placebo according to the assigned dose cohort.

07

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as accessed by CTCAE v6.0

    after single and multiple doses

    Time frame: SAD: Screening period up to day 29 MAD: Screening period up to day 50

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  2. Area under the concentration-time curve from time 0 to the last measurable time point (AUClast)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  3. Area under the concentration time curve from time 0 to infinity (AUCinf)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  4. Percent of AUC extrapolated to infinity (AUC_Extrap)

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  5. Time to maximum concentration (Tmax)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  6. Elimination half-life (t1/2)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  7. Apparent volume of distribution (Vz/F)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  8. Apparent clearance (CL/F)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  9. Anti-SYH2069 antibody (ADA)

    after single and multiple doses

    Time frame: SAD: Pre-dose at day 1 to day 29. MAD: Pre-dose at day 1 to day 50.

  10. Mean change in plasma glucose from baseline

    after single and multiple doses

    Time frame: SAD: Baseline up to Day 29 MAD: Baseline up to Day 50

  11. Mean change in insulin from baseline

    after single and multiple doses

    Time frame: SAD: Baseline up to Day 29 MAD: Baseline up to Day 50

  12. Mean change in C-peptide from baseline

    after single and multiple doses

    Time frame: SAD: Baseline up to Day 29 MAD: Baseline up to Day 50

  13. Mean change in glucagon from baseline

    after single and multiple doses

    Time frame: SAD: Baseline up to Day 29 MAD: Baseline up to Day 50

  14. Mean change in HbA1c from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 50

  15. Change in body weight from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 50

  16. Change in waist circumference from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 50

  17. Mean change in Total Cholesterol(TC) from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  18. Mean change in Triglycerides(TG) from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  19. Mean change in Low-Density Lipoprotein Cholesterol(LDLC) from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  20. Mean change in High-Density Lipoprotein Cholesterol(HDLC) from baseline

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  21. Change in blood pressure from baseline

    after multiple doses

    Time frame: MAD:Baseline up to Day 50

  22. Change in Visceral Fat from baseline via Bioelectrical Impedance Analysis (BIA)

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  23. Change in Body Fat from baseline via Bioelectrical Impedance Analysis (BIA)

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  24. Change in Skeletal Muscle from baseline via Bioelectrical Impedance Analysis (BIA)

    after multiple doses

    Time frame: MAD: Baseline up to Day 29

  25. Corrected QT(QTc) interval

    Baseline- and placebo-corrected QTcF ( ΔΔQTcF )

    Time frame: SAD: Pre-dose at day 1 to day 8 MAD: Pre-dose at day 1 to day 29

08

Study locations

1 site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 6 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 30, 2026
StartActual
Jan 10, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07736391
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Jan 10, 2026
Primary completion
Jul 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2069

Start the discussion